KBP Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, KBP Biosciences sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

KBP Biosciences: 12 sponsored US clinical trials, none currently recruiting.

KBP Biosciences sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 1 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 1 trials.

Top-decile sponsor footprint

KBP Biosciences ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 1

Study of KBP-7072 in Healthy Male and Female Subjects

NCT05507463
TERMINATED Phase 3

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

NCT04968184
COMPLETED Phase 1

Mass Balance Study of KBP-5074 in Healthy Male Subjects

NCT04634812
COMPLETED Phase 1

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
COMPLETED Phase 1

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

NCT04534699
COMPLETED Phase 1

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

NCT04532957
COMPLETED Phase 2

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

NCT03574363
COMPLETED Phase 1

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT03340753
COMPLETED Phase 1

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
COMPLETED Phase 1

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

NCT02654626
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

NCT02653014
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics of KBP-7072

NCT02454361

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 1
Phase 3 1

Therapeutic Areas

Healthy Subjects 1
Chronic Kidney Disease 1
Healthy 1

How the KBP Biosciences early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 1 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Healthy Subjects (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

KBP Biosciences: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

KBP Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share KBP BiosciencesAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
KBP Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

KBP Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this KBP Biosciences page

12 registered trials is a research-attention snapshot, not an endorsement of KBP Biosciences or any single study.

  • None of KBP Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Subjects is the condition KBP Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

KBP Biosciences pipeline card: 12 registered trials from official public datasets.Report a data error.